Dermatological Drugs - Italy

Italy

In Italy, the revenue in the Dermatological Drugs market is estimated to reach €300.70m by 2024.
It is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 5.20%, leading to a market volume of €387.50m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, with an estimated amount of €10,820.00m in 2024.
Italy's dermatological drug market is experiencing a surge in demand for innovative skincare products driven by a growing health-conscious population.

Key regions: United Kingdom, Canada, Japan, Europe, China

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The demand for dermatological drugs in Italy has been increasing steadily in recent years.

Customer preferences: Italian consumers are becoming more aware of the importance of skincare and are willing to invest in products that can improve the health and appearance of their skin. There is a growing demand for dermatological drugs that can treat a variety of skin conditions, including acne, eczema, and psoriasis. Italian consumers are also interested in natural and organic skincare products, which has led to the development of a market for dermatological drugs made from natural ingredients.

Trends in the market: One of the key trends in the dermatological drugs market in Italy is the increasing use of biologics. Biologic drugs are becoming more popular because they are highly effective in treating a range of skin conditions, including psoriasis and eczema. Another trend in the market is the growing demand for over-the-counter (OTC) dermatological drugs. Many Italian consumers prefer to use OTC products for mild skin conditions, rather than seeking prescription medications.

Local special circumstances: Italy has a large aging population, which has contributed to the growth of the dermatological drugs market. As people age, they are more likely to develop skin conditions that require medical treatment. Additionally, Italy has a high prevalence of skin cancer, which has led to an increased demand for dermatological drugs that can treat and prevent this condition.

Underlying macroeconomic factors: The Italian economy has been recovering slowly in recent years, which has led to an increase in consumer spending. This has contributed to the growth of the dermatological drugs market, as consumers are more willing to invest in high-quality skincare products. Additionally, the Italian government has been investing in healthcare infrastructure, which has improved access to medical treatment for many consumers. This has also contributed to the growth of the dermatological drugs market, as more people are able to seek treatment for skin conditions.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.